Overview

Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The primary aim of the study is to compare the glucose response to low-dose glucagon (single 150 µg dose) administered immediately before aerobic exercise versus the glucose response to oral glucose intake (0.75 g/kg body weight) during exercise in individuals with AHCL-treated T1D.

Phase:

N/A

Details

Lead Sponsor:

Steno Diabetes Center Copenhagen

Treatments:

Glucagon